Dr. Rosenblatt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1611 NW 12th Ave
# M851
Miami, FL 33136Phone+1 305-243-1000Fax+1 305-243-9927
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1981 - 1983
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1980 - 1981
David Geffen School of Medicine at UCLAClass of 1980
Certifications & Licensure
CA State Medical License 1981 - Present
FL State Medical License 2003 - 2026
NY State Medical License 1995 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- America's Top Doctors for Cancer Castle Connolly, 2006-2013
- Top Doctors:South Florida Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma Start of enrollment: 1997 Nov 01
- Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors Start of enrollment: 1999 Apr 01
Publications & Presentations
PubMed
- 1 citationsAntibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FA...Ankita P Sankar, Hyun-Mi Cho, Seung-Uon Shin, Tal Sneh, Sundaram Ramakrishnan
Cancer Research Communications. 2024-03-11 - 31 citationsThree-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew Ulrickson
Blood. 2024-02-08 - Time is of the Essence: Using Extended Hemin Treatment for a Case of Severe Acute Intermittent Porphyria.Smriti Rajita Kumar, Diana Byrnes, Mahmoud Mahfouz, Joseph Rosenblatt, Cynthia Levy
ACG Case Reports Journal. 2022-07-01
Press Mentions
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024- Sylvester Fuels Junior Faculty Members’ Research Careers with American Cancer Society GrantsMay 18th, 2023
Synergys Awarded NCI Grant to Develop SYN001 for Triple-Negative Breast CancerOctober 9th, 2017- Join now to see all
Grant Support
- Host Defense Regulation By HTLV-1National Cancer Institute2009–2011
- Augmentation Of Anti-Tumor Activity In The Absence Of B CellsNational Cancer Institute2007–2011
- HSV Amplicon Activation Of Innate And Adaptive ImmunityNational Cancer Institute2004–2008
- Antibody Fusion Proteins For The Therapy Of CancerNational Cancer Institute2002
- Chemokine Enhanced Immune Therapy Of LymphomaNational Cancer Institute2001–2002
- Chemokine Enhanced Immune Therapy Of LymphomaNational Cancer Institute2000–2001
- Antibody Fusion Proteins For The Therapy Of CancerNational Cancer Institute1999–2001
- Inhibition Of HIV 1 Using A Mutant Trna PrimerNational Institute Of Allergy And Infectious Diseases1997–2000
- Enhanced Immunogenicity Of Neuroblastoma Cells By Genetic EngineeringNational Cancer Institute1997–1998
- Core--Gene And Cellular Therapy CoreNational Institute Of Allergy And Infectious Diseases1994–1997
- Regulation Of Gene Expression In HTLV Type I/IINational Cancer Institute1990–1994
- Pathogenesis Of HTLV-1 Associated MyelopathyNational Cancer Institute1990–1992
- Pathogenic Mechanisms In HTLV-1 Linked DiseasesNational Cancer Institute1991
- Role Of Novel X-Region Proteins In Htlv-1/11National Cancer Institute1987–1991
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
